PRKCE and obesity disorder: While MetAP2 inhibitors show promise in treating T2DM and obesity, and while Gαi, PKCε, and TRAM significantly impact these conditions, no direct studies have linked MetAP2 inhibition to the modulation of these proteins to alleviate T2DM or obesity.